For citation: Bekyashev A.Kh., Golanov A.V., Tushev A.A., Moldovanov V.A., Banov S.M.. Adjuvant chemotherapy of newly diagnozed low grade gliomas. Golova i sheya. Rossijskij zhurnal Head and neck Russian Journal. 2019;7(3):49–57 (in Russian).
Low-grade gliomas (LGG, WHO – World Health Organization Grade II) are the tumors of neuroepithelial origin, accounting for 15-45% of all primary brain lesions. According to H. Ohgaki and P. Kleihues (2005), the average time for progression of glioma to glioblastoma is about 5.3 years, and from WHO Grade III glioma to glioblastoma is 1.4 years. The median overall survival (OS) for LGG is 186 months; the 5-year OS varies from 54.6 to 88.4%, the 5-year progression-free survival (PFS) is about 37% to 55%; 8-year PFS — 37%, and 10-year OS – 67.1%. The life expectancy of patients with newly diagnosed gliomas is about 6 to 8 years in average, but it can reach 20 years, according to some studies. The factors for predicting continued growth after surgical treatment are _the patient’s age, initial neurological status, radical surgical removal, and tumor localization. Despite the fact that, according to neurosurgeons, all patients underwent total tumor removal, 58 (59%) of 98 patients had residual tumor (≤1 cm resection margin in all directions), which was revealed on T2-weighted MRI images. In 31 (32%) patients, residual tumor was observed within 1–2 cm in all directions from resection margin, and in 9 patients (9%) – within 2 cm or even more. Currently, there are no completed randomized trials on the use of chemotherapy in patients with LGG after surgical treatment; all studies belong to the 3rd evidence level. The need for adjuvant therapy for LGG is based on the risk factors for relapse in each individual case.
Key words: low-grade gliomas, diffuse astrocytomas, WHO Grade 2 gliomas, chemotherapy for low-grade gliomas, chemotherapy for WHO Grade 2 gliomas, diffuse astrocytoma chemotherapy
The authors declare no conflict of interest.
Source of financing: not specified.
For citation: Bekyashev A.Kh., Golanov A.V., Tushev A.A., Moldovanov V.A., Banov S.M.. Adjuvant chemotherapy of newly diagnozed low grade gliomas. Golova i sheya. Rossijskij zhurnal Head and neck Russian Journal. 2019;7(3):49–57 (in Russian).
The authors are responsible for the originality of the data presented and the possibility of pub-lishing illustrative material – tables, figures, photographs of patients.
摘要
低度神经胶质瘤（LGG，WHO-世界卫生组织II级）是神经上皮起源的肿瘤，占所有原发性脑部病变的15-45％
根据H. Ohgaki和P. Kleihues（2005）的研究，神经胶质瘤发展为胶质母细胞瘤的平均时间约为5.3年，而从 WHO III级神经胶质瘤发展为胶质母细胞瘤的平均时间为1.4年。 LGG的中位总生存期（OS）为186个月； 5年OS 从54.6％到88.4％不等，5年无进展生存期（PFS）约为37％至55％； 8年PFS-37％，10年OS-67.1％。
根据一些研究，新诊断出的神经胶质瘤患者的平均寿命约为6至8年，但可以达到20年。预测手术治疗后持续增长 的因素是患者的年龄，初始神经系统状况，彻底的手术切除和肿瘤的位置。尽管根据神经外科医师的事实，所有 患者均进行了全部肿瘤切除，但98例患者中有58例（59％）残留肿瘤（在各个方向上≤1 cm切除切缘），这在T2 加权MRI图像上可以看出。在31例（32％）患者中，从切除边缘到各个方向的1-2 cm内均观察到残留肿瘤，而9 例（9％）在2 cm甚至更大范围内观察到残留肿瘤。目前，尚无关于LGG患者手术治疗后使用化学疗法的完整随 机试验。所有研究均属于第三证据级别。 LGG辅助治疗的需要是基于每个病例复发的危险因素。
关键词：低度神经胶质瘤，弥漫性星形细胞瘤，WHO 2级神经胶质瘤，低度神经胶质瘤化疗，WHO 2级神经胶质 瘤化学疗法，弥漫性星形细胞瘤化疗。
作者声明没有利益冲突。
资金来源：未指定。
引用：Bekyashev A.Kh., Golanov A.V., Tushev A.A., Moldovanov V.A., Banov S.M.. Adjuvant chemotherapy of newly diagnozed low grade gliomas. Golova i sheya. Rossijskij zhurnal = Head and neck. Russian Journal. 2019;7(3):49–57 (in Russian).
作者对所提供数据的独创性以及发布说明性材料（表格，数字，患者照片）负责。